Search Results - "Lesley A. Inker"

GFR Estimation: From Physiology to Public Health by Levey, Andrew S., MD, Inker, Lesley A., MD, MS, Coresh, Josef, MD, MS, PhD

“…Estimating glomerular filtration rate (GFR) is essential for clinical practice, research, and public health. Appropriate interpretation of estimated GFR (eGFR)…”
Get full text

KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD by Inker, Lesley A., MD, Astor, Brad C., PhD, Fox, Chester H., MD, Isakova, Tamara, MD, Lash, James P., MD, Peralta, Carmen A., MD, Kurella Tamura, Manjula, MD, Feldman, Harold I., MD, MSCE

“…The National Kidney Foundation–Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) guideline for evaluation, classification, and stratification of chronic…”
Get full text

A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease by Delgado, Cynthia, Baweja, Mukta, Crews, Deidra C., Eneanya, Nwamaka D., Gadegbeku, Crystal A., Inker, Lesley A., Mendu, Mallika L., Miller, W. Greg, Moxey-Mims, Marva M., Roberts, Glenda V., St. Peter, Wendy L., Warfield, Curtis, Powe, Neil R.

“…In response to a national call for re-evaluation of the use of race in clinical algorithms, the National Kidney Foundation (NKF) and the American Society of…”
Get full text

Uses of GFR and Albuminuria Level in Acute and Chronic Kidney Disease by Levey, Andrew S., Grams, Morgan E., Inker, Lesley A.

“…Testing for kidney disease is routine in clinical practice. This review focuses on advances in clinical evaluation of the glomerular filtration rate and…”
Get full text

GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration by Levey, Andrew S., MD, Inker, Lesley A., MD, MS, Matsushita, Kunihiro, MD, PhD, Greene, Tom, PhD, Willis, Kerry, PhD, Lewis, Edmund, MD, de Zeeuw, Dick, MD, PhD, Cheung, Alfred K., MD, Coresh, Josef, MD, PhD

“…The US Food and Drug Administration currently accepts halving of glomerular filtration rate (GFR), assessed as doubling of serum creatinine level, as a…”
Get full text

GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials by Inker, Lesley A, Heerspink, Hiddo J L, Tighiouart, Hocine, Levey, Andrew S, Coresh, Josef, Gansevoort, Ron T, Simon, Andrew L, Ying, Jian, Beck, Gerald J, Wanner, Christoph, Floege, Jürgen, Li, Philip Kam-Tao, Perkovic, Vlado, Vonesh, Edward F, Greene, Tom

“…Surrogate end points are needed to assess whether treatments are effective in the early stages of CKD. GFR decline leads to kidney failure, but regulators have…”
Get full text

GFR as the “Gold Standard”: Estimated, Measured, and True by Levey, Andrew S., MD, Inker, Lesley A., MD, MS

Get full text

Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C by Inker, Lesley A, Schmid, Christopher H, Tighiouart, Hocine, Eckfeldt, John H, Feldman, Harold I, Greene, Tom, Kusek, John W, Manzi, Jane, Van Lente, Frederick, Zhang, Yaping Lucy, Coresh, Josef, Levey, Andrew S

“…This study presents an equation for estimating the glomerular filtration rate that uses both creatinine and cystatin C. It performs better than equations with…”
Get full text

Cystatin C versus Creatinine in Determining Risk Based on Kidney Function by Shlipak, Michael G, Matsushita, Kunihiro, Ärnlöv, Johan, Inker, Lesley A, Katz, Ronit, Polkinghorne, Kevan R, Rothenbacher, Dietrich, Sarnak, Mark J, Astor, Brad C, Coresh, Josef, Levey, Andrew S, Gansevoort, Ron T

“…In this meta-analysis of 16 studies, investigators evaluated the use of cystatin C, alone or with creatinine, to calculate the estimated glomerular filtration…”
Get full text

Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy by Thompson, Aliza, Carroll, Kevin, A Inker, Lesley, Floege, Jürgen, Perkovic, Vlado, Boyer-Suavet, Sonia, W Major, Rupert, I Schimpf, Judith, Barratt, Jonathan, Cattran, Daniel C, S Gillespie, Barbara, Kausz, Annamaria, W Mercer, Alex, Reich, Heather N, H Rovin, Brad, West, Melissa, Nachman, Patrick H

“…IgA nephropathy (IgAN) is an important cause of ESKD for which there are no approved therapies. A challenge for evaluating treatments for IgAN is the usual…”
Get full text

Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials by Collier, Willem, Haaland, Benjamin, Inker, Lesley A, Heerspink, Hiddo J L, Greene, Tom

“…Surrogate endpoints, such as those of interest in chronic kidney disease (CKD), are often evaluated using Bayesian meta-regression. Trials used for the…”
Get full text

Early Change in Proteinuria as a Surrogate End Point for Kidney Disease Progression: An Individual Patient Meta-analysis by Inker, Lesley A., MD, MS, Levey, Andrew S., MD, Pandya, Kruti, MS, Stoycheff, Nicholas, MD, Okparavero, Aghogho, MBBS, MPH, Greene, Tom, PhD

“…Background It is controversial whether proteinuria is a valid surrogate end point for randomized trials in chronic kidney disease. Study Design Meta-analysis…”
Get full text

Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality by Coresh, Josef, Turin, Tanvir Chowdhury, Matsushita, Kunihiro, Sang, Yingying, Ballew, Shoshana H, Appel, Lawrence J, Arima, Hisatomi, Chadban, Steven J, Cirillo, Massimo, Djurdjev, Ognjenka, Green, Jamie A, Heine, Gunnar H, Inker, Lesley A, Irie, Fujiko, Ishani, Areef, Ix, Joachim H, Kovesdy, Csaba P, Marks, Angharad, Ohkubo, Takayoshi, Shalev, Varda, Shankar, Anoop, Wen, Chi Pang, de Jong, Paul E, Iseki, Kunitoshi, Stengel, Benedicte, Gansevoort, Ron T, Levey, Andrew S

“…IMPORTANCE: The established chronic kidney disease (CKD) progression end point of end-stage renal disease (ESRD) or a doubling of serum creatinine…”
Get full text

GFR Decline as an Alternative End Point to Kidney Failure in Clinical Trials: A Meta-analysis of Treatment Effects From 37 Randomized Trials by Inker, Lesley A., MD, MS, Lambers Heerspink, Hiddo J., PhD, Mondal, Hasi, MPH, Schmid, Christopher H., PhD, Tighiouart, Hocine, MS, Noubary, Farzad, PhD, Coresh, Josef, MD, PhD, Greene, Tom, PhD, Levey, Andrew S., MD

“…Background There is increased interest in using alternative end points for trials of kidney disease progression. The currently established end points of…”
Get full text

Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation by Greene, Tom, Ying, Jian, Vonesh, Edward F, Tighiouart, Hocine, Levey, Andrew S, Coresh, Josef, Herrick, Jennifer S, Imai, Enyu, Jafar, Tazeen H, Maes, Bart D, Perrone, Ronald D, Del Vecchio, Lucia, Wetzels, Jack F M, Heerspink, Hiddo J L, Inker, Lesley A

“…Randomized trials of CKD treatments traditionally use clinical events late in CKD progression as end points. This requires costly studies with large sample…”
Get full text

Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data by Grams, Morgan E, Sang, Yingying, Ballew, Shoshana H, Matsushita, Kunihiro, Astor, Brad C, Carrero, Juan Jesus, Chang, Alex R, Inker, Lesley A, Kenealy, Timothy, Kovesdy, Csaba P, Lee, Brian J, Levin, Adeera, Naimark, David, Pena, Michelle J, Schold, Jesse D, Shalev, Varda, Wetzels, Jack F M, Woodward, Mark, Gansevoort, Ron T, Levey, Andrew S, Coresh, Josef

“…Decline in eGFR is a biologically plausible surrogate end point for the progression of CKD in clinical trials. However, it must first be tested to ensure…”
Get full text

GFR Decline and Subsequent Risk of Established Kidney Outcomes: A Meta-analysis of 37 Randomized Controlled Trials by Lambers Heerspink, Hiddo J., PhD, Tighiouart, Hocine, MS, Sang, Yingying, MSc, Ballew, Shoshana, PhD, Mondal, Hasi, MPH, Matsushita, Kunihiro, MD, PhD, Coresh, Josef, MD, PhD, Levey, Andrew S., MD, Inker, Lesley A., MD, MS

“…Background The currently established end points for clinical trials of progression of chronic kidney disease (CKD) are end-stage renal disease and doubling of…”
Get full text

A Dynamic Predictive Model for Progression of CKD by Tangri, Navdeep, MD, PhD, FRCPC, Inker, Lesley A., MD, MS, Hiebert, Brett, MSc, Wong, Jenna, MSc, Naimark, David, MD, MSc, FRCPC, Kent, David, MD, MS, Levey, Andrew S., MD

“…Background Predicting the progression of chronic kidney disease (CKD) is vital for clinical decision making and patient-provider communication. We previously…”
Get full text

A Metabolome-Wide Association Study of Kidney Function and Disease in the General Population by Sekula, Peggy, Goek, Oemer-Necmi, Quaye, Lydia, Barrios, Clara, Levey, Andrew S, Römisch-Margl, Werner, Menni, Cristina, Yet, Idil, Gieger, Christian, Inker, Lesley A, Adamski, Jerzy, Gronwald, Wolfram, Illig, Thomas, Dettmer, Katja, Krumsiek, Jan, Oefner, Peter J, Valdes, Ana M, Meisinger, Christa, Coresh, Josef, Spector, Tim D, Mohney, Robert P, Suhre, Karsten, Kastenmüller, Gabi, Köttgen, Anna

“…Small molecules are extensively metabolized and cleared by the kidney. Changes in serum metabolite concentrations may result from impaired kidney function and…”
Get full text

Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study by Chin, Melanie P, Bakris, George L, Block, Geoffrey A, Chertow, Glenn M, Goldsberry, Angie, Inker, Lesley A, Heerspink, Hiddo J L, O'Grady, Megan, Pergola, Pablo E, Wanner, Christoph, Warnock, David G, Meyer, Colin J

“…Increases in measured inulin clearance, measured creatinine clearance, and estimated glomerular filtration rate (eGFR) have been observed with bardoxolone…”
Get more information